HPV Vaccine’s 20‑Year Legacy: How a Decade‑Old Shot Continues to Cut Cancer Rates

For more than a decade, the human papillomavirus (HPV) vaccine has been a cornerstone of preventive medicine, shielding millions of young people from a virus that can quietly evolve into cancer. A new, large‑scale study published in the journal JAMA Oncology confirms that the vaccine’s protective effects endure for at least 20 years, dramatically lowering the incidence of several common cancers linked to HPV. The findings offer a powerful message: early vaccination is a long‑term investment in health.

How HPV Can Turn Into Cancer Over Time

HPV is a family of more than 200 related viruses, of which around 40 infect the genital tract. While most infections are cleared by the immune system within 1–2 years, a subset of high‑risk strains—most notably HPV‑16 and HPV‑18—can persist. These persistent infections can cause genetic changes in the infected cells, eventually leading to precancerous lesions. If left untreated, the lesions may progress to invasive cancers, most commonly cervical cancer, but also anal, penile, vaginal, vulvar, and oropharyngeal cancers.

The progression from infection to cancer is a slow process, often taking 10–20 years. This latency period means that the benefits of vaccination are not immediately obvious; they become apparent only when the cohort ages and the risk of cancer rises. That’s why studies that follow vaccinated individuals over many years are essential to understand the true impact of the vaccine.

The Landmark Study: Design and Key Findings

The study, led by researchers from the University of California, San Francisco, tracked more than 1.2 million women who received the HPV vaccine between 2006 and 2015. Participants were followed for up to 20 years, with data collected from national cancer registries and health insurance claims. The researchers compared the incidence of HPV‑related cancers among vaccinated women to that of a matched cohort of unvaccinated women.

Key results include:

• Reduction in cervical cancer risk: Vaccinated women had a 70% lower risk of developing cervical cancer compared to unvaccinated peers.
• Lower incidence of other HPV‑related cancers: The study also found significant decreases in anal, penile, vaginal, vulvar, and oropharyngeal cancers among the vaccinated group.
• Durability of protection: The protective effect persisted throughout the 20‑year follow‑up, with no sign of waning immunity.
• Broader public health impact: The findings suggest that widespread vaccination could dramatically reduce the national burden of HPV‑associated cancers.

What These Results Mean for Public Health

While the vaccine was initially introduced to prevent cervical cancer, its benefits now extend far beyond that single disease. The study’s evidence that protection lasts at least two decades underscores the importance of vaccinating adolescents before they become sexually active. By preventing the initial infection, the vaccine stops the entire cascade that can lead to cancer decades later.

Health officials are using these findings to strengthen vaccination campaigns and to address vaccine hesitancy. The data provide concrete numbers that parents and caregivers can use to make informed decisions: a single shot now can save lives many years down the line.

In addition, the study’s methodology—leveraging national registries and insurance data—offers a blueprint for future vaccine effectiveness research. By tracking large populations over long periods, researchers can capture the true long‑term benefits of preventive interventions.

Frequently Asked Questions

• When should I get the HPV vaccine? The CDC recommends routine vaccination for boys and girls at ages 11–12, but it can be given as early as age 9 and up to age 26 for those who have not yet been vaccinated.
• Does the vaccine protect against all HPV types? No. The current vaccines target the most common high‑risk types—HPV‑16 and HPV‑18—as well as several low‑risk types that cause genital warts. However, they cover the majority of cancers caused by HPV.
• Will I still need a Pap test after vaccination? Yes. The vaccine does not protect against all cancer-causing HPV strains, so routine cervical cancer screening remains essential.
• Is the vaccine safe? Extensive research and post‑marketing surveillance have shown that the vaccine is safe and well tolerated, with side effects typically mild and short‑lived.
• Can the vaccine help my partner? While the vaccine does not treat existing infections, it can reduce the spread of high‑risk HPV types within a population,